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Intraoperative radiotherapy (IORT) for early stage breast cancer is a technique for partial 
breast irradiation. There are several technologies in clinical use to perform breast IORT. 
Regardless of technique, IORT generally refers to the delivery of a single dose of radiation 
to the periphery of the tumor bed in the immediate intraoperative time frame, although 
some protocols have performed IORT as a second procedure. There are two large 
prospective randomized trials establishing the safety and efficacy of breast IORT in early 
stage breast cancer patients with sufficient follow-up time on thousands of women. The 
advantages of IORT for partial breast irradiation include: direct visualization of the target 
tissue ensuring treatment of the high-risk tissue and eliminating the risk of marginal miss; 
the use of a single dose coordinated with the necessary surgical excision thereby reduc-
ing omission of radiation and the selection of mastectomy for women without access to 
a radiotherapy facility or unable to undergo several weeks of daily radiation; favorable 
toxicity profiles; patient convenience and cost savings; radiobiological and tumor micro-
environment conditions which lead to enhanced tumor control. The main disadvantage 
of IORT is the lack of final pathologic information on the tumor size, histology, margins, 
and nodal status. When unexpected findings on final pathology such as positive margins 
or positive sentinel nodes predict a higher risk of local or regional recurrence, additional 
whole breast radiation may be indicated, thereby reducing some of the convenience 
and low-toxicity advantages of sole IORT. However, IORT as a tumor bed boost has 
also been studied and appears to be safe with acceptable toxicity. IORT has potential 
efficacy advantages related to overall survival related to reduced cardiopulmonary radia-
tion doses. It may also be very useful in specific situations, such as prior to oncoplastic 
reconstruction to improve accuracy of adjuvant radiation delivery, or when used as a 
boost in higher risk patients to improve tumor control. Ongoing international clinical trials 
are studying these uses and follow-up data are accumulating on completed studies.
Keywords: breast cancer, intraoperative radiotherapy, breast conservation therapy, partial breast irradiation, 
radiation therapy
iNTRODUCTiON
Partial breast irradiation has been established as a suitable treatment option for appropriately selected 
women with early stage breast cancer by numerous clinical trials dating back to the 1990s. There 
are several techniques which have been studied to accomplish irradiation of the periphery of the 
lumpectomy bed as sole therapy after lumpectomy, which is the target volume for any form of partial 
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breast treatment. Intraoperative radiotherapy (IORT) is one such 
technique. The major difference between IORT techniques and 
other forms of APBI is timing of the procedure. IORT is most 
often performed at the time of breast surgery as a single dose, 
while other APBI techniques are performed post-operatively, 
using target volumes are typically based on CT images and deliv-
ering multiple fractions. IORT requires specialized radiotherapy 
equipment, and there are several technologies available to provide 
IORT partial breast irradiation, which deliver treatment with 
either electrons or 50  kV X-rays. IORT has the advantage of 
completing the breast-conserving surgery and, in most cases, the 
partial breast irradiation as one combined procedure. All forms 
of APBI treat a smaller volume of normal tissue than whole breast 
radiation (WBRT), thereby reducing the potential lung and car-
diac toxicities of radiation treatment, and reducing the overall 
treatment time compared with whole breast irradiation. IORT 
has the additional advantage of delivering a single dose at the time 
of surgery, potentially reduces non-compliance to post-operative 
radiation, and mastectomy rates among women without ready 
access to a radiotherapy center. There are two recently published 
large prospective randomized controlled trials comparing post-
lumpectomy standard whole breast irradiation to IORT, one 
using electrons and one using 50 kV photons, which have shown 
low-local recurrence rates for IORT with acceptable toxicity and 
excellent overall survival outcomes. These trials begin to inform 
our knowledge of selection criteria for optimal breast IORT 
candidates and provide the first evidence of outcomes and toxic-
ity when using these techniques. Patient selection is important 
when recommending IORT, as the final pathology is not available 
at the time of treatment, so in order to avoid the potential use 
of subsequent whole breast irradiation, careful pre-operative, 
and intraoperative assessment can help ensure that high-risk 
features such as positive margins or positive sentinel nodes are 
minimized. As all techniques of partial breast irradiation leave 
some volume of the breast unirradiated, understanding of the 
selection criteria for each of the various techniques is critical 
information for clinicians when considering which patients may 
be appropriately treated with IORT or any other APBI technique. 
This review will discuss the clinical trial data, patient selection 
criteria, advantages and disadvantages of partial breast IORT, and 
published guidelines.
RADiOBiOLOGY AND TUMOR 
MiCROeNviRONMeNT
A common calculation for assessing the efficacy of different 
dose fractionations in radiotherapy is the relative biological 
effectiveness (RBE = Dx/D). This parameter allows comparisons 
of radiation-induced cellular damage at a designated dose (D) 
relative to a reference dose (Dx) for the selected endpoint, such as 
percentage of cells surviving after 2 Gy (SF2). It is well known that 
the RBE of photons increases with decreasing energy, explained 
by a decrease in energy of secondary electrons with an increase 
in linear energy transfer (1, 2). Cell culture experiments utilizing 
cell survival methods such as SF2 confirm enhanced biological 
effects after exposure to lower energy X-rays. Brenner et al. mod-
eled RBE at clinically relevant doses, at which the RBE for 40 kV 
photons was about 1.4 compared with 4 mV. Since effective RBE 
increases with depth this creates a less rapid fall-off of the biologi-
cally weighted dose at measured depth. A published review sum-
marized RBEs for 10% cell survival established using different 
systems and tumor cell types for low energy X-rays (10–240 kV) 
to range from 1.1 and 1.7 (3). The RBE of 50  kV electronic 
brachytherapy sources has been estimated to exceed biological 
effectiveness by 40–50% over Co60 or Ir192 (4). Other investigators 
have employed a linear-quadratic formula to model the RBE of 
50  kV X-rays modeled as an equivalent to a fractionated dose 
of 2 Gy (EQD2) as a function of depth, with the probability of 
local control estimated from clinical dose response data (5). This 
model resulted in a theoretical “sphere of equivalence” to explain 
the improved tumor control probability in the high-dose cloud 
near the applicator surface, where residual microscopic disease is 
most likely to be located, and compensating for a somewhat lower 
tumor control probability as the distance from the applicator 
increases. Overall local control patterns thus exhibited a different 
spatial pattern but were ultimately very similar to convention-
ally fractionated external beam irradiation. In the example of 
IORT for breast cancer, higher RBE for low-energy X-rays may 
result in higher tumor control rates in the breast tissue in closest 
proximity to the surgical excision bed and effectively eliminating 
the “marginal miss.” In addition, cell culture data suggest that 
the RBE decreased at increasing distance, potentially reducing 
the effective dose to adjacent critical structures including heart 
and lung (6). The tumor bed intraoperatively is better oxygen-
ated, which may also improve cell kill probability. There may 
also be some radiobiological advantages in using a higher dose 
per fraction in breast cancer, which has been estimated to have 
an alpha/beta ratio of around 4, therefore may demonstrate a 
higher radioresponsiveness to higher doses per fraction (7). The 
biologically equivalent dose (BED) for an alpha/beta of 4 in the 
linear-quadratic model for a prescribed single dose of 10 Gy is 
isoeffective to about 24 in 2 Gy fractions.
The microenvironment of the breast cancer cells likely plays 
a critical role as well in the risk of tumor recurrence, and this 
microenvironment is altered by the use of immediate radiation 
peri-operatively. Belletti et  al. collected wound fluid from the 
lumpectomy cavity over 24 h after surgery, half of whom had 
IORT at the time of lumpectomy (8). The wound fluid was 
used to stimulate several breast cancer and control cell lines 
and analyzed for cell growth and motility. Normal wound fluid 
stimulated proliferation, migration, and invasion in breast 
cancer cell lines, while these effects were abrogated by wound 
fluid from immediately irradiated samples. The radiated wound 
fluid had altered expression cytokines, suggesting that the 
radiation had altered protein expression. Fabris et al. collected 
tissues from irradiated using IORT and non-irradiated tissue 
from breast cancer patients after surgery, and profiled the tis-
sue for microRNA expression (9). IORT radiation changed the 
wound response by inducing expression of miRNA 223 in the 
peri-tumoral tissue, which downregulated expression of epi-
dermal growth factor (EGF) and EGF receptor activation. This 
downregulation cascade prevented breast cancer cell growth 
and reduced local recurrence in mice models. A number of 
other studies have noted the stimulatory effect of wound fluid 
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on breast cancer cells, suggesting a role of the fluid in cancer cell 
proliferation and possibly local recurrence, an effect that may 
be muted by immediate radiation, with its abrogating effect on 
protein expression. Clinical trial data are clinically consistent 
with these concepts and investigations of the biological effects of 
immediate high-dose radiation on the wound fluid and immu-
nologic environment are ongoing.
iO(e)RT TeCHNOLOGieS
The Intrabeam® system (Carl Zeiss Meditec, Dublin, CA, USA) 
uses a 50 kV photon beam mobile X-ray unit that has been in 
clinical use since 1999 (10). The miniaturized accelerator pro-
duces an electron beam that is accelerated to the tip of a drift 
tube generating an isotropic point source of low-energy X-rays. 
The source is permanently integrated into the treatment unit, 
and is calibrated daily and externally yearly. This system has been 
designed for single fraction IORT and is calibrated at a single 
dose rate and output factor. IORT is delivered using multiuse 
solid state spherical applicators of size ranges 1.5–5 cm diameter. 
Treatment time typically runs 20–45  min depending upon the 
applicator size used.
The Axxent® System (Xoft Inc., Sunnyvale, CA, USA) is an 
electronic brachytherapy machine in clinical use since 2009 (11). 
The radiation source is a miniature, electronic, high-dose rate 
low-energy X-ray tube integrated into a flexible multi-lumen 
catheter producing 40–50 Kv X-rays at the catheter tip. The Axxent 
system was originally designed for fractionated balloon-based 
partial breast irradiation using variable currents and voltages to 
allow for changes in dose rates or depths, and can also be used 
for single fractions. The source is disposable and used for up to 
10 fractions, with disposable balloons of spherical and ellipsoidal 
sizes (3–6 cm spherical and 5–6 × 7 cm elliptical), over treatment 
times of 10–20 min. Both technologies can be used in a standard 
operating room with portable shielding only.
Mobile electron accelerators use electrons energies ranging 
from 3 to 12 MeV. The lumpectomy cavity of the breast is treated 
with a cone inserted intraoperatively (12). Electrons are more 
penetrating than low-energy X-rays, requiring breast tissue to 
be mobilized and for shields to be inserted into the posterior 
lumpectomy cavity in order to shield tissues inside the thorax. 
Doses of 20–21 Gy usually delivered at a low-electron energy for 
the measured depth. This technology is often notated as intraop-
erative electron radiation therapy (IOERT).
iO(e)RT AS SOLe PARTiAL BReAST 
RADiATiON
To date, there are two large prospective randomized trials 
published using breast IO(E)RT, the TARGIT-A trial and the 
ELIOT trial. TARGIT-A compared conventional WBRT (EBRT) 
to single dose IORT (TARGIT) and enrolled 3,451 patients from 
33 centers in 10 countries between the years 2000 and 2012. This 
study used a non-inferiority statistical design which anticipated a 
15% probability of adverse pathologic features on final pathology 
leading to additional WBRT after initial IORT (13). There were 
pre-specified strata described as IORT at the time of lumpectomy 
(pre-pathology), or IORT performed during a subsequent proce-
dure at a different time (post-pathology).
Women enrolled to TARGIT-A were age 45  years or older 
with operable unifocal invasive ductal carcinoma. Per eligibility 
criteria pathologic findings requiring subsequent WBRT after 
IORT included positive excision margins, extensive intraductal 
component, or the presence of invasive lobular carcinoma. 
Participating centers could prospectively specify additional other 
factors. Overall, 22% of women enrolled in the pre-pathology and 
3.6% of those in the post-pathology strata received additional 
WBRT after randomization to IORT. The majority enrolled had 
lower risk pathologic features, including ≤2  cm (87%), low to 
intermediate grade (85%), negative nodes (84%), estrogen recep-
tor positive (93%), and mammographic detection (63%). With 
median follow-up of 2.5 years of the whole cohort and over 1,200 
patients with 5-year median follow-up, for the primary endpoint 
of in-breast recurrence (IBR), the investigators reported 5-year 
IBR in the EBRT arm of 1.3%, and in the TARGIT arm of 3.3%, a 
2% difference which was within the pre-specified 2.5% non-infe-
riority margin (p = 0.042). The impact of the timing of IORT was 
analyzed between the two strata. For pre-pathology stratum, IBR 
was 1% in the EBRT arm and 2.1% in the TARGIT arm (p = 0.31). 
For post-pathology stratum, IBR was 1.7% in the EBRT arm and 
5.4% in the TARGIT arm (p = 0.069). These findings prompted 
the trialists to conclude that pre-pathology timing was more 
optimal. Overall survival was higher in the TARGIT arm (3.9%) 
compared with the EBRT arm (5.3%; p = 0.099), mainly due to 
higher rates of cardiopulmonary deaths. Toxicity comparisons 
including hematoma requiring treatment, post-operative infec-
tion, delayed wound healing, and all major toxicities were similar 
between the two arms.
The largest series outside of the TARGIT-A trial using 50 kV 
IORT has been reported by the TARGIT-R North American 
multi-institutional IORT retrospective registry trial (14). 
Nineteen institutions participated in this registry and reported 
outcomes on 822 women treated from 2007 through 2013 with 
minimum 6 months follow-up and a median follow-up of 2 years. 
Registrants were treated with IORT without (n =  537) or with 
WBRT (n = 110) or IORT as intended boost (n = 115). As is typi-
cal of APBI studies and registries, patients were mainly lower risk, 
or meeting American Society for Radiation Oncology (ASTRO) 
2009 “suitable” criteria, with a median age of 67, <2 cm (90%), 
estrogen receptor positive (91%), Her2 non-amplified (89%), 
grade 1–2 (83%), without lymphovascular invasion (91%), and 
sentinel node negative (89%). Interestingly, 52% of registrants 
had a pre-operative breast MRI performed. Post-operative WBRT 
was recommended in 17% of IORT patients due to unfavorable 
pathologic findings, and 14% of registrants received IORT as 
a planned boost. A small number (n  =  60) had delayed IORT 
as a second procedure rather than at the time of lumpectomy. 
Local IBRs were seen in 2.3% (n = 19 of 822), and axillary nodal 
recurrences in 0.2% (n = 2), at a median time to recurrence of 
19  months. One death was attributed to breast cancer. Local 
recurrence by type of IORT was reported as follows: IORT alone, 
2.4%; secondary IORT, 6.6%; IORT + WBRT, 1.7%; IORT boost, 
1.8%. Thirteen of 19 local recurrences occurred >1 cm from the 
lumpectomy site. Several of these patients had higher risk features 
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including ER negative tumors or positive sentinel nodes but 
elected not to undergo WBRT. Complications were low, including 
post-operative seroma in 9%, hematoma in 1.5%, and infection 
requiring antibiotics in 2.8%. The early results of this large ret-
rospective registry are similar to those seen in the TARGIT-A 
randomized trial. There is also an ongoing prospective United 
States registry study, TARGIT-US (15), which should complete 
accrual this year.
The ELIOT study had a similar design to the TARGIT-A, 
but used mobile electron technology to deliver IORT. It was a 
single institution study completed by the Institute Milan. This 
trial randomized 1,305 women between the years 2000 and 2007 
between external conventional whole breast irradiation (EBRT) 
(50  +  10  Gy boost) and single dose electron IOERT (21  Gy) 
with no additional WBRT (16). The study statistical design was 
an equivalence endpoint, with a pre-specified margin for local 
recurrence of 7.5% after IOERT. Women eligible for the study 
had stage I–II invasive breast cancer up to 2.5 cm in size between 
ages 48 and 75 years old. Lower risk tumors were pre-dominant, 
with patient characteristics including estrogen receptor positive 
in 90%, Her2 negative in 97%, and negative nodes in 74%. With 
median follow-up of 5.8 years, 5 years IBR was recorded in an 
unexpectedly low percentage in the EBRT arm (0.4%) as well as 
in the IOERT arm (4.4%), which was within the pre-specified 
equivalence margin of 7.5% (p < 0.0001). There was no differ-
ence in overall survival (96.8 and 96.9%, respectively; p = 0.59). 
Cutaneous toxicities were significantly better for all recorded 
endpoints in the IOERT arm, although a higher incidence of fat 
necrosis was seen after IOERT, with no overall differences in other 
side effects including breast fibrosis, retraction, pain, or burning. 
The ELIOT trialists concluded that the unselected population 
helped to define stricter selection criteria which could result in a 
lower IBR rate. They identified risk factors associated with local 
recurrence after IOERT as tumor size >2 cm, grade 3, 4, or more 
positive nodes, and triple negative histology.
The published randomized trials and large multi-institutional 
studies, provide guidance in selecting appropriate patients for 
breast IORT, and provide the basis for guidelines and consensus 
statements of selection criteria. The ASTRO consensus guideline 
was updated in 2017 to include a key question on breast IO(E)
RT. The statement notes that IO(E)RT use should be restricted to 
women who otherwise meet “suitable” criteria for partial breast 
irradiation, and Coverage with Evidence Development on a 
registry or trial applies to low-energy X-ray IORT while await-
ing longer follow-up on accrued clinical trials (17). The limited 
follow-up time was a major concern of this panel. There have 
been published commentary which disagree with some of the 
conclusions of the ASTRO consensus statement on IORT, includ-
ing by a group representing other professional societies and IORT 
users, which highlighted inconsistencies in interpretation of the 
TARGIT-A data (18). TARGIT investigators advocate use of the 
study criteria and offering patients WBRT as was done on the 
study when pathologic features indicative of more diffuse disease 
are present on final pathology. Similarly, the ELIOT investiga-
tors discussed the potential for use of stricter selection criteria 
for IOERT than used in the trial, with initial use or inclusion of 
WBRT when those features are present on final pathology. With 
any type of IO(E)RT, radiation most commonly delivered at the 
time of surgery when final pathologic features are not yet avail-
able, therefore selection criteria should be based on the informa-
tion available prior to as well as during surgery. Many surgeons 
and radiation oncologists prefer to have rigorous intraoperative 
assessment of sentinel nodes and margins to assist in decision 
making and patient selection.
Toxicity and Cosmesis
In studies using 50  kV X-rays, several have reported acute 
and late toxicity profiles after IORT ±  WBRT. In the original 
TARGIT-A publication, all clinically significant complications 
occurred in 3.3% or fewer patients, including hematoma or 
seroma requiring intervention, infection, wound healing, 
or any grade 3 toxicity, and were similar between IORT and 
WBRT arms. In the study update published in 2013, it was noted 
that complications at 6 months showed no difference between 
arms for any wound-related complications, with fewer grade 
3–4 skin toxicities after IORT. Keshtgar reported cosmesis up 
to 4 years after IORT on a TARGIT-A subprotocol as assessed 
by photograph-analyzing software. IORT patients were about 
twice as likely to have excellent or good cosmetic scores as 
WBRT treated patients (19). One German institution examined 
their 48 TARGIT-A enrolled patients in a subgroup analysis of 
post-treatment mammogram findings (20). They noted a higher 
rate of radiographic fat necrosis after IORT (56%) than after 
conventional WBRT (24%), and more scar calcifications as well. 
Sperk et al. noted no differences between IORT ± WBRT versus 
WBRT with respect to fibrosis, breast edema, lymphedema, 
pain, or hyperpigmentation (21). Fibrosis was higher after 
IORT + WBRT (37.5%) than after IORT alone (6%) or WBRT 
only (18%) at 3  years. Telangiectasias were not seen in any 
IORT only patients, compared with 17% of women after 
WBRT ± IORT. The Copenhagen group conducted a subgroup 
analysis of post-treatment pain in their enrolled TARGIT-A 
cohort (n =  244) conducted using patient reported outcomes 
data, and found that persistent pain was reported in 34% of 
WBRT patients compared with 25% of IORT patients (22).
In studies using electron IOERT, the ELIOT trial reported on 
the subset of patients in whom toxicity data were available, noting 
that side effect profiles significantly favored IOERT compared 
with WBRT, especially as related to skin toxicity, with less ery-
thema, hyperpigmentation, dryness, and pruritis (all p < 0.04). 
No differences were recorded for fibrosis, pain, or burning 
sensation. Only radiologic presence of necrosis was higher in the 
IOERT group. The ELIOT group randomly selected 119 patients 
treated with sole IOERT for further late toxicity assessment using 
standard rating scales (23). At a median of 6 years, grade 2 fibrosis 
was noted in 32% and grade 3 fibrosis in 6%. Excellent or good 
cosmesis was scored by patients in 77% and by physicians in 84%. 
The Netherlands group compared institutional data for women 
treated with IOERT (n =  26) or conventional WBRT (n =  45) 
based on seven asymmetry features (24). Features favoring 
IOERT with smaller differences between treated and untreated 
breast included breast contour, relative breast area, and breast 
overlap. Excellent and good cosmesis after IOERT was scored as 
88% by patients and 96% by physicians.
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Quality of Life
Increasingly, study of quality of life accompanies more tradi-
tional outcomes endpoints and influences patient preferences 
and informed consent discussions for patients and their provid-
ers facing breast cancer treatment. Investigators in Australia 
conducted a survey of Western Australia breast cancer health 
professionals and reported that among those surveyed, 3–7.5% 
considered breast IORT unacceptable treatment at any risk of 
local recurrence, 18–21% considered IORT acceptable at risks 
equivalent to that of WBRT, while 56–59% considered IORT 
acceptable if associated with a 1–3% increased local recurrence 
risk (25). In a survey of patient preference considering treatment 
options of breast IORT or fractionated multi-week whole breast 
irradiation which described to participants alternative increases 
in rates of local recurrence risk over 10 years, this survey found 
that patients accepted a median increase in local recurrence 
risk for IORT of 2.3% (26). In addition, 91% surveyed would 
accept IORT if the treatment were equivalent or associated with 
a slightly higher risk of local recurrence compared with WBRT. 
Another quality of life study among a subgroup of German 
patients enrolled in the TARGIT-A trial administered the 
EORTC QLQ-C30 and BR23 survey instruments (27). Patients 
in the IORT alone arm indicated significantly less general pain, 
breast, and arm symptoms and better overall functioning than 
patients in the WBRT arm.
BReAST iO(e)RT iN OTHeR  
CLiNiCAL CONTeXTS
Intraoperative radiotherapy, as with all types of APBI, is less 
well studied in conjunction with breast-conserving surgery for 
ductal carcinoma in situ (DCIS). The recent update of the ASTRO 
APBI consensus statement now classifies APBI for pure DCIS as 
“suitable” when meeting certain specific criteria. A California 
group has published the only series to date using 50 kV IORT 
for patients with DCIS. In this series, selection criteria included 
tumor size <4 cm on pre-operative imaging with pure DCIS on 
biopsy and deemed resectable with breast conservation (28). 
Thirty-five patients had IORT, with a mean tumor size of 1.5 cm. 
Five patients had close or positive margins, two of whom had 
mastectomy due to extent of DCIS in the specimen, and three 
had re-excision followed by WBRT, for a 14% rate of additional 
treatment after surgery plus IORT. The 3-year local recurrence 
rate was 5.7%.
A study from the Milan group used IOERT in conjunction 
with nipple-sparing mastectomy, comparing 800 patients receiv-
ing IOERT to the retroareolar region of the nipple to 201 patients 
with nipple-sparing mastectomy followed by delayed one-dose 
radiation later (29). At median follow-up of 20  months, they 
noted nipple-areolar necrosis in 3.5%, and nipple removal in 
5%. Of the 1.4% local recurrences, none were seen in the nipple, 
but at the site of the primary tumor. No difference in outcomes 
was noted between the two techniques. This report does not 
discuss any comparison with patients who have not received any 
radiation to the nipple-areolar complex. A second series using 
50 kV IORT single dose of 16 Gy after nipple-sparing mastectomy 
describes only seven patients with 7 months follow-up, with no 
acute toxicity attributable to radiation, no necrosis of the nipple 
complex or local recurrences (30).
In these special clinical scenarios, further data are needed 
to define the appropriate role of IORT. The direct visualization 
and elimination of the possibility of marginal miss makes IORT 
an attractive technique in  situations where accuracy of dose 
targeting is particularly critical, such as women with higher risk 
cancers, as being investigated in the TARGIT-B trial of IORT 
versus conventional boost. Areas for further study of the efficacy 
and toxicity of IORT may include as sole therapy for lower risk 
DCIS, as a boost prior to planned oncoplastic reconstruction, 
and as part of re-treatment after prior whole breast irradiation 
for limited local recurrence.
iO(e)RT BOOST
A boost dose to the periphery of the surgical lumpectomy bed 
has been shown to further lower the risk of local recurrence, 
especially for younger women, women with higher grade, triple 
negative or larger tumors, and those with positive margins or 
extensive lymphovascular invasion (31). The tissue in closest 
proximity to the primary cancer has the highest density of residual 
microscopic cells and is therefore at highest risk for local recur-
rence. Several institutional studies have reported using IORT as a 
boost with planned WBRT to follow. The theoretical advantages 
of using IORT as a boost include the ability to directly visualize 
the tumor bed and thereby avoid marginal misses when boosting 
a CT-based volume. The same BED, oxygenation, and biological 
advantages theoretically present for single dose IORT may be 
relevant for IORT boost as well, and are under investigation. 
Several studies using either IOERT (intraoperative electrons) 
or 50 kV IORT as a boost have been reported. Ongoing studies 
going IORT boost include the TARGIT-B(oost) (32) and HIOP 
trials (33).
Intraoperative electron radiation therapy boost has been 
reported as a pooled analysis by the International Society of 
Intraoperative Radiotherapy (34). In this analysis, 1,109 unse-
lected patients from seven European centers, 60% of whom had 
at least one high risk factor, were treated similarly with IOERT 
boost at a median dose of 10 Gy and a subsequent whole breast 
dose of 50–54 Gy. After a median follow-up of 5 years, the local 
recurrence risk was 0.8%, half seen in the index quadrant. Risk 
factors for recurrence included high grade, age under 40, and ER 
negative. Upon examining the impact of delays from IOERT boost 
to WBRT, no impact on local recurrence of delays up to 140 days 
was seen. The Salzburg IOERT group conducted a matched-pair 
analysis of IOERT boost and external electron boost patients, 
who had IBR rates at 10 years of 1.6 and 7.2%, respectively (35).
Low-energy X-rays IORT as a boost has been reported in two 
cohort series. One multicenter pilot study treated with 20 Gy to 
cavity surface intraoperatively followed by 45–50 Gy whole breast 
in 299 women undergoing lumpectomy. After a median follow-
up of 5 years, the observed local recurrence rate was 2.7% (36). 
A single institution series of 197 patients received an IORT boost 
of 18–20 Gy then 46–50 Gy whole breast, reporting a 5-year local 
relapse free survival of 97% (37).
TABLe 1 | Prospective randomized controlled trials of partial breast irradiation compared to whole breast radiation.








Hungary Polgar et al. (47,48) MC Brachy (69%) 
or electrons (31%)








Florence Livi et al. (49) IMRT 260 5.0 84% 86 9 89 95 1.5% 99.4%
WBRT 260 83% 82 12 82 96 1.5% 96.6%
GEC-ESTRO Strnad et al. (50) MC Brachy 633 6.6 86% 84 6 94 92 1.44% 97.3%
WBRT 551 83% 86 4 95 91 0.92% 95.6%
TARGIT-A Vaidya et al. (13) IORT ± WBRT 1,721 2.5 >45, 98% 96 0 82 90 3.3% 96.1%
WBRT 1,730 99% 95 0 84 93 1.3% 94.7%
ELIOT Veronesi et al. (16) IOERT 651 5.8 93% 87 0 74 90 4.4% 96.8%
WBRT 654 93% 84 0 73 91 0.4% 96.9%
PBI, partial breast irradiation; MC, multicatheter; Brachy, brachytherapy; WBRT, whole breast radiation; IORT, intraoperative radiotherapy; IOERT, intraoperative electron radiotherapy; 
IMRT, intensity modulated radiotherapy; F/U, follow-up; ER, estrogen receptor; pTis, pathologic ductal carcinoma in situ; NR, not reported.
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Regardless of technique the toxicity of IORT boost appears 
to be acceptable. The virtual complete skin sparing associated 
with use of IORT is likely to have a positive impact on any 
cutaneous toxicity profiles. Acutely there are no reports of 
increased post-operative infections or delayed wound healing. 
Late fibrosis has been reported to range from about 0 to 15% for 
grade 3 toxicity, depending upon technique and dose. Cosmesis 
does not seem to be compromised in the studies described 
when compared with conventional boost techniques, although 
assessment tools have varied. Lemanski has reported the long-
est term experience in using IOERT boost, reporting 9-year 
outcomes on 50 women receiving 10  Gy IORT then 50  Gy 
whole breast, with no grade 3 fibrosis and 14% grade 2 fibrosis 
(38). Mayo Arizona conducted a prospective study of 10  Gy 
IOERT then 48  Gy to the whole breast, and reported a 3.8% 
6-year local recurrence rate, with excellent or good cosmesis 
in 87% of patients (39). An Australian group reported that 55 
patients treated with 5 Gy at 1 cm IORT boost then 50 Gy whole 
breast had no local recurrences at 3 years, but grade 3 fibrosis 
was 15% (40). There is one report of IOERT boost (12 Gy) fol-
lowed by hypofractionated whole breast (37.05 Gy in 13 daily 
fractions of 2.85 Gy) in 204 pre-menopausal women. Reporting 
only acute toxicity, grade 3 skin toxicity was 4%, grade 2 skin 
toxicity was 29%; late skin toxicity at 12 months was grade 3 
and 4 in one patient each (41).
For context in comparison, the EORTC boost trial, the 5- and 
10-year rates of moderate to severe fibrosis was reported in 11 
and 28% of boost patients compared with 10 and 13% on the no 
boost arm. In this study, at 3 years, excellent and good cosmesis 
was somewhat worse in the boost arm compared with no boost, 
71 versus 86%, respectively (42, 43).
There are several reports of using IORT boost in conjunction 
with breast-conserving surgery and WBRT in special patient 
cohorts. One retrospective series reported on IORT boost after 
neoadjuvant chemotherapy in 61 patients and a contemporane-
ous consecutive cohort of 55 patients who received a conven-
tional external beam boost, all receiving WBRT (44). At 4 years 
follow-up, there was no difference in 5-year local recurrence 
(9.8% with IORT and 8.3% with external boost), and there was a 
better overall survival in the IORT arm (97 versus 82%) related 
to fewer non-breast cancer deaths. The Salzburg group has also 
reported IORT boost in a retrospective series of triple negative 
patients undergoing breast conservation, with an 8-year actuarial 
local recurrence rate of 11%, all of those recurrences occurring in 
high-grade cancers (45).
A German group has reported on IORT boost in the setting 
of oncoplastic reconstruction. This is a particularly appealing 
clinical scenario for the use of an IORT boost, as the oncoplastic 
reconstruction which immediately follows the definitive onco-
logic surgery to remove the cancerous cells can eradicate any clear 
delineation of the tumor bed and preclude the use of external beam 
boost, causing some patients to be underdosed. Performing IORT 
after the lumpectomy but prior to the oncoplastic rearrangement 
eliminates the risk of target volume miss, the possibility of dis-
semination of microscopic disease during the reconstruction, or 
inability to identify the boost target on post-operative treatment 
planning image sets. However, minimal data exist to support the 
efficacy of this approach. The Cologne group has used IORT boost 
in 149 patients who also underwent an oncoplastic reconstruc-
tion (glandular rotation or mammoplasty), and have reported 
only post-operative toxicity, with a 2% seroma formation rate. 
Additional outcome and efficacy data from this and other series 
will be welcome (46).
CONCLUSiON
Breast IO(E)RT is currently primarily a technique for partial 
breast irradiation which has been well established as an option for 
patients who are otherwise appropriate candidates for APBI. Two 
large randomized trials, the TARGIT A trial establishing 50 kV 
IORT and ELIOT establishing electron based IOERT, both have 
published excellent results regarding local control and acceptable 
toxicity. While local recurrence was slightly higher after IORT 
in both studies, it was within the clinically relevant range seen 
in numerous other clinical trials of various radiation techniques, 
including APBI and WBRT approaches (see Table 1). Patient pref-
erence analyses have shown that some women will accept the risk 
of a small increase in local recurrence in order to preserve their 
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